The company is set to acquire InSite Vision, a US based eye care company and the deal is reportedly of Rs. 300 crore. InSite Vision is a developer of specialty ophthalmology drugs and has a pipeline of eight clinical candidates in various stages.
| Subscribe To Our Free Newsletter |
